References
- Arrambide K., Toto R.D. Tumor lysis syndrome. Semin. Nephrol. 1993; 309: 1094–1104
- Benekli M., Savas M.C., Güllü I.H., Kadayifci A., Akpek G., Kars A., Giiler R., Kansu E., Tekuzman G., Firat D. Tumor lysis syndrome following single dose mitoxantrone. Chemotherapy 1995; 41: 470–472
- Sparano J., Ramirez M., Wiernik P.H. Increased recognition of corticosteroid induced tumor lysis syndrome in non-Hodgkin's lymphoma. Cancer 1990; 65: 1072–1073
- Simmons E.D., Somberg K.A. Acute tumor lysis syndrome after intrathecal methotrexate administration. Cancer 1991; 67: 2062–2065
- Shapiro W.R., Young D.R., Mehta B.M. Distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N. Engl. J. Med. 1975; 293: 161–166
- Bode U., Magrath I.T., Bleyer W.A., Poplack D.G., Glaubiger D.L. Active transport of methotrexate from cerebrospinal fluid in humans. Cancer Res. 1980; 40: 2184–2187
- Jolivet J., Cowan K.H., Curt G.A., Cleadeninn N.J., Chabner B.A. The pharmacology and clinical use of methotrexate. N. Engl. J. Med. 1983; 309: 1094–1104
- Bleyer W.A., Drake J.C., Chabner B.A. Neurotoxicity and elevated cerebrospinal fluid methotrexate concentration in meningeal leukemia. N. Engl. J. Med. 1973; 289: 770–773